JW신약

067290KOSDAQ의약품 제조업

60.5 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40

News Sentiment12.5 / 25

Momentum15.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but PBR raises overvaluation concerns. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

JW Shinapharm primarily engages in the manufacturing and sales of pharmaceuticals, building a systematic sales network through joint marketing with JW Chungwa Pharmaceutical. Its subsidiary, JW Crigen, specializes in cell therapy products. In 2024, the company achieved consolidated sales of 93 billion won and an operating profit of 10 billion won. Key products include antifungal medications, dermatological treatments, and internal medicine drugs.

Number of Employees

173people

Average Salary

69.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.24Industry Average 14.806.5Point

Lower than industry avg (good)

PBR

2.78Industry Average 1.040.0Point

2.7x industry avg (risky)

ROE

46.53Industry Average 4.427.0Point

10.5x industry avg (excellent)

Debt Ratio

5.17Industry Average 11.986.5Point

Half of industry avg (excellent)

Trend 2023~20253.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.8% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲25.9% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -11.2% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (61%)

Current 2,020Won52-week high 2,48052-week low 1,294

1-month return3.0Point

1m -0.74% (flat)

Volume trend6.0Point

Volume surge

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral정기주주총회결과2026-03-26
Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral사업보고서 (2025.12)2026-03-18